Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bovine viral diarrhea virus glycoprotein E2 (BVDV E2) is an envelope protein essential for pestivirus entry into host cells, forming disulfide-linked homodimers and heterodimers with E1 that mediate receptor binding and membrane fusion.[1][4] Its ectodomain features a unique three-domain architecture: two Ig-like domains (I and II) followed by an elongated β-stranded domain III with a novel fold, including a conserved histidine (His762) for pH sensing during endosomal acidification and extensive glycosylation and disulfide bonds for stability.[1] E2 determines cellular tropism via interactions with receptors like CD46 and harbors major neutralizing antibody epitopes, particularly in domains I and II.[1][4] Structurally, it lacks classic fusion motifs, suggesting E1 as the primary fusogen with E2 providing scaffold support, a model relevant to related hepatitis C virus.[1] BVDV particles, enriched in cholesterol and sphingolipids, display low E2 abundance on their ~50 nm envelope, highlighting E2's role in morphogenesis and entry.[2][4] As a veterinary pathogen target, E2 inhibition could block bovine infections, though no approved drugs exist.[3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bovine viral diarrhea virus glycoprotein E2 (E2).